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A B S T R A C T 
Recent experimental studies showed an important role of endothelium derived relaxing factor for 
cavernous smooth muscle relaxation. Since nitr ic oxide seems to account for the biological actions 
of endothelium derived relaxing factor, a study was done to examine a possible role of the nitric 
oxide donor linsidomine chlorhydrate (SIN-1) i n the treatment of erectile dysfunction. 
To determine a therapeutically useful dose 0.1, 0.2, 0.5 and 1 mg. S I N - 1 were injected intracav-
ernously i n patients w i t h erectile dysfunction. Each dose was given to 2 patients. Then, 63 patients 
received 1 mg. S I N - 1 , including 7 who had prolonged erections to minimal doses of papaverine plus 
phentolamine and 4 who did not respond w i t h a fu l l erection to other pharmacological agents. 
Intracavernous injection of S I N - 1 induced a dose-dependent erectile response by increasing the 
arterial inflow and relaxing cavernous smooth muscles. Of the patients 29 had a fu l l , 21 an almost 
f u l l and 13 a moderate erection to 1 mg. S I N - 1 . There were no systemic or local side effects. I n the 
patients w i t h prolonged erections to papaverine plus phentolamine the mean duration of a ful l 
erectile response to S I N - 1 was 57 minutes. Compared to the responses to a papaverine (15 mg./ml.) 
and phentolamine (0.5 mg./ml.) mixture, the erection induced by S I N - 1 was superior in 10, 
comparable i n 47 and inferior i n 6 patients. 
Our data suggest a possible role for S I N - 1 i n the treatment of erectile dysfunction. Possible 
advantages may be that erection is induced by a mechanism similar to that occurring physiologically, 
a decreased risk of inducing prolonged erections and low therapy costs. 
K E Y W O R D S : peni le e r e c t i o n , i m p o t e n c e , n i t r i c oxide 
Cavernous smooth muscles have a crucial role in penile 
erection. Relaxation of the arterial and sinusoidal cavernous 
smooth muscles induces an erection by decreasing peripheral 
resistance, entrapping blood within the sinusoids and restrict­
ing cavernous outflow.1 In vascular smooth muscle endothelium 
derived relaxing factor is an important physiological mecha­
nism for relaxation.2 The current view is that nitric oxide or a 
nitric oxide-containing compound, synthetized from L-argi-
nine, accounts for the biological actions of endothelium derived 
relaxing factor.3 Recent in vitro studies on rabbit and human 
penile tissues have shown that nitric oxide or a nitric oxide-
containing compound, probably released from nerves, has a role 
in the regulation of cavernous smooth muscle tone.4"7 In vivo 
studies in rabbits further support a role for the L-arginine/ 
nitric oxide pathway in penile erection.8 
These experimental data suggest that in the treatment of 
erectile dysfunction use of the L-arginine/nitric oxide pathway 
may be an interesting approach, since i t would resemble the 
physiological sequence of events in erection. Linsidomine chlor­
hydrate (SIN-1) is the active metabolite of the antianginal drug 
molsidomine9 (N-ethoxycarbonyl-3-morpholino-sydnonimine) 
and it is believed to liberate nitric oxide nonenzymatically 
(nitric oxide donor). Preliminary results showed that SIN-1 
produces an erection in patients with erectile dysfunction.1 0 We 
examined the effects of intracavernous application of SIN-1 in 
63 men with erectile dysfunction, and evaluated its possible 
therapeutic potential in the treatment of erectile dysfunction. 
A c c e p t e d for p u b l i c a t i o n M a r c h 13, 1992. 
S u p p o r t e d by grants S t i 9 6 / 2 - 2 f r o m t h e D e u t s c h e F o r s c h u n g s ­
gemeinschaft a n d the S w e d i s h M e d i c a l R e s e a r c h C o u n c i l ( N o . 6837) . 
P A T I E N T S A N D M E T H O D S 
SIN-1 was injected intracavernously in 63 patients from our 
impotence clinic. Before entering the study the patients under­
went a comprehensive evaluation regarding the etiology of the 
erectile dysfunction, including case history, physical examina­
tion, sexual case history (by a psychiatrist), blood laboratory 
studies, pharmaco-Doppler ultrasound, single potential analy­
sis of cavernous electrical activity evaluation11 and pharmaco­
logical testing. 1 2 When indicated by case history or the afore­
mentioned examinations,12 pharmaco-angiography or caverno-
sometry was done. In case the standardized medication of 15 
mg./ml. papaverine and 0.5 mg./ml. phentolamine, with a max­
imal dose of 3 ml., did not induce a full erection (at least 3 
intracavernous injections were done), prostaglandin E l (maxi­
mal dose 40 μg.) was applied. In case of incomplete erection to 
prostaglandin E l a combination of 10 ^g. prostaglandin E l and 
5 ßg. calcitonin gene-related peptide13 was tried. All injections 
were done with the patient in the supine position. Only 1 dose 
a day was injected. To enhance reproducibility the patients 
were advised to restrain from psychogenic or reflexogenic stim-
ulation. The erectile response was evaluated by a urologist 10, 
20 and 30 minutes after the injection. 
After the diagnostic evaluation all patients were injected 
with SIN-1 intracavernously. Before the injection the patients 
were extensively informed about the study and about possible 
side effects (prolonged erections, systemic side effects, such as 
decreased blood pressure with unconsciousness, cavernous f i -
brosis and infection). After the explanation written consent 
was obtained from each patient. The study was approved by 
the Ethics Committee of the University of Hannover (approval 
No. 532). 
SIN-1 is officially approved for treatment of coronary spasms 
1437 
1438 S T I E F A N D A S S O C I A T E S 
F I G . 1. I n t r a c a v e r n o u s i n j e c t i o n of 0.5 mg. S I N - 1 i n 51 -year -o ld 
p a t i e n t w i t h v e n o g e n i c a n d a r t e r i o g e n i c erect i le d y s f u n c t i o n induced 
s i g n i f i c a n t i n c r e a s e i n p e n i l e a r t e r i a l b lood flow ve loc i ty d u r i n g 140 
m i n u t e s ( c o n t i n u o u s w a v e D o p p l e r u l t r a s o u n d , 8 M H z . probe) . 1, 
D o p p l e r s i g n a l s before S I N - 1 . 2, 3 m i n u t e s after i n t r a c a v e r n o u s in jec ­
t i o n of 0.5 mg. S I N - 1 ( E l ) . 3, 10 m i n u t e s after S I N - 1 ( E 2 ) . 4, 35 
m i n u t e s after S I N - 1 ( E 4 ) . 
F I G . 2. R e c o r d i n g of c a v e r n o u s e lectr ic a c t i v i t y ( frequency range 0.5 
to 500 H z . ) w i t h 2 needle e lectrodes , 1 i n e a c h c o r p u s , i n 39 -year -o ld 
p a t i e n t w i t h erect i le d y s f u n c t i o n , negat ive o r g a n i c f indings a n d high 
p r o b a b i l i t y of p s y c h o g e n i c etiology, a, u p p e r r e c o r d i n g shows n o r m a l 
e l e c t r i c a c t i v i t y i n f l a c c i d s tate ( r e c o r d e d d u r i n g 40 m i n u t e s ) , s y n c h r o n ­
ous i n b o t h c a v e r n o u s bodies w i t h u p p e r t r a c i n g i n r i g h t a n d lower i n 
left c a v e r n o u s body. 6, 20 s e c o n d s after i n t r a c a v e r n o u s in ject ion of 1 
mg . S I N - 1 . L o w e r r e c o r d i n g s h o w s d r a m a t i c a l l y r e d u c e d cavernous 
e l e c t r i c a c t i v i t y i n b o t h c a v e r n o u s bodies , w i t h o n l y short last ing 
p o t e n t i a l s of low a m p l i t u d e ( a r r o w s ) i n left c o r p u s . T h i s reduced 
c a v e r n o u s e lectr ic a c t i v i t y l a s t e d more t h a n 60 m i n u t e s (end of regis­
t r a t i o n ) . 
and for angiography of the coronary arteries. The dosage rec­
ommended by the manufacturer is 0.4 to 1 mg. Therefore, we 
applied 0.1 mg. in 2 patients, 0.2 mg. in 2 and 0.5 mg. in 2. 
Since a main purpose of this study was to evaluate a therapeu­
tically useful dose, considering effect versus possible side ef­
fects, such as pain, prolonged erections and systemic reactions, 
ail patients (including the aforementioned 6) received 1 mg. 
Nine patients were also given 2 mg. SIN-1, since 1 mg. induced 
only an insufficient (less than category E5) erectile response. 
In 6 of these 9 patients SIN-1 was considered the last thera­
peutic alternative regarding available drugs for autoinjection 
therapy. Since a possible therapeutic use of SIN-1 was to be 
evaluated, patients receiving 2 mg. SIN-1 were advised to use 
additional reflexogenic and/or psychogenic stimulation to im­
prove the erectile response. The first 2 of these 9 patients were 
medical doctors. Before the injection ail patients receiving 2 
mg. SIN-1 were informed about the unusually high dose with 
possible severe systemic side effects (hypotension and hypo­
volemic shock). The local response to SIN-1 was measured by 
inspection and palpation by a urologist; the erectile response 
was classified into 6 categories: E0—no response, El—mini ­
mum tumescence, E2—medium tumescence, E3—full tumes­
cence without rigidity, E4—full tumescence with medium rigid­
ity and E5—full erection. Bidirectional Doppler sonography of 
the 4 penile arteries was done in the first 6 injections, 2 patients 
each receiving 0.1, 0.2 and 0.5 mg. SIN-1. Single potential 
analysis of cavernous electrical activity was done in 2 patients 
receiving 1 mg. SIN-1. Pulse and blood pressure were closely 
monitored in the first 8 patients. During the entire procedure 
the patient was in the supine position. 
R E S U L T S 
At the dosages used intracavernous application of SIN-1 
induced an erectile response in all patients. The erectile re­
sponse, measured by tumescence and rigidity, as well as by 
arterial flow velocity, was dose-dependent. Intracavernous in­
jection of 0.1 mg. SIN-1 (2 patients) induced a medium tumes­
cence without rigidity (E2) after a mean of 15 minutes and 
lasting for 45 minutes. By Doppler sonography a significant 
increase in cavernous arterial flow was observed for a mean of 
85 minutes. Intracavernous injection of 0.2 mg. SIN-1 (2 pa­
tients) induced an almost full erection (E4 to E5) for 40 minutes 
and a significant increase in arterial flow was observed for 135 
minutes. Intracavernous injection of 0.5 mg. SIN-1 (2 patients) 
induced a full erection (E5) in 1 patient for 40 minutes and full 
tumescence with medium rigidity (E4) in 1, and an increase in 
arterial inflow was observed for a mean of 150 minutes (fig. 1). 
Recording of cavernous electrical activity showed disappear­
ance of the potentials about 20 seconds after the intracavernous 
injection of 1 mg. SIN-1 in both patients (fig. 2). Intracavernous 
injection of 1 mg. SIN-1 was done in 63 patients and induced 
a full erection (E5) in 29, full tumescence with medium rigidity 
(E4) in 21 and full tumescence (E3) in 13. 
In 9 of the patients with an incomplete erectile response (E3) 
to 1 mg. SIN-1 pharmacocavernosometry showed venous leak­
age. These patients were injected with 2 mg. SIN-1. Among the 
9 patients who received intracavernous injection of 2 mg. SIN-
1 an almost full erection (E4 to E5) was observed in 4, while 5 
achieved an erectile response (E4) comparable to that obtained 
with 1 mg. SIN-1. All 4 patients with an almost full erection 
after 2 mg. SIN-1 achieved a full erection (E5) with additional 
stimulation. Comparing the maximal erectile response to SIN-
1 to that of the combination of papaverine and phentolamine, 
SIN-1 was superior in 10 of the 63 patients, comparable in 47 
and inferior in 6. 
In 2 of 4 patients with insufficient erectile response to 
maximal doses of papaverine (45 mg.) plus phentolamine (1.5 
mg.), prostaglandin E l (40 Mg.) and the combination of pros­
taglandin E l (10 Mg.) plus calcitonin gene-related peptide (5 
M g . ) 1 4 intracavernous injection of 2 mg. SIN-1 induced an 
almost full erection (E4 to E5), which became a full erection 
with additional stimulation. Both patients are currently on 
SIN-1 autoinjection therapy. 
A total of 4 patients did not respond to maximal doses of 
papaverine plus phentolamine or prostaglandin E l with a full 
erection. The combination of 10 μ%. prostaglandin E l plus 5 
Mg. calcitonin gene-related peptide induced a full erection (E5) 
for 60 minutes. In these patients intracavernous injection of 1 
mg. SIN-1 induced only an incomplete erectile response (E3 or 
E4). In 2 other patients responding better to the papaverine-
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phentolamine combination the diagnostic evaluation was 
highly suspicious for pure psychogenic impotence. 
A total of 7 patients showed a pure neurogenic etiology for 
the erectile dysfunction on diagnostic evaluation. A dosage of 
1 mg. SIN-1 was injected into 6 patients with long lasting full 
erections to relatively small doses of the combination of papav­
erine and phentolamine. With a mean dose of 0.33 ml. (5 mg. 
papaverine and 0.16 mg. phentolamine) 4 of the 6 men had a 
mean full erectile duration of 230 minutes; 2 of them presented 
with 2 episodes of prolonged erection. Another patient was 
transferred to us because multiple prolonged erections devel­
oped of about 40 hours to doses of 20 mg. papaverine. In these 
7 patients intracavernous injection of 1 mg. SIN-1 induced a 
full erection lasting for 40 to 90 minutes (mean 57 minutes). 
I n all but 1 patient the injection of SIN-1 induced no objective 
or subjective systemic side effects. One patient reported sweat­
ing after intracavernous injection of 2 mg. SIN-1. No patient 
reported pain or burning during or after the intracavernous 
injection of SIN-1. Of the patients who were on papaverine and 
phentolamine autoinjections 4 noticed subjectively that intra­
cavernous application of SIN-1 was much more comfortable 
than injection of the papaverine-phentolamine mixture. 
D I S C U S S I O N 
Our study shows that the intracavernous injection of SIN-1 
induces a dose-dependent erectile response. By Doppler sonog­
raphy we could demonstrate that this erectile response is ac­
companied by a dramatic increase in cavernous arterial blood 
flow. In vitro studies showed cavernous smooth muscle relaxa­
tion to SIN-1. 7 These findings are in agreement with our 
recordings of cavernous electrical activity before and after 
intracavernous injection of SIN-1. We found an almost com­
plete disappearance of cavernous electrical activity after SIN-
1, which shows that the erectile response to intracavernous 
SIN-1 is due to cavernous smooth muscle relaxation.11 
Comparing the maximal erectile responses, the erection in­
duced by SIN-1 was superior to that produced by the combi­
nation of papaverine and phentolamine in 10 of 63 patients, 
comparable in 47 patients and inferior in 6. The mechanisms 
behind the effects of the combination are complex, and prob­
ably not only include the phosphodiesterase inhibiting effects 
of papaverine and the α-adrenoreceptor blocking effect of phen­
tolamine but additional actions. SIN-1 is believed to liberate 
nitric oxide nonenzymatically, which, in turn, stimulates gua-
nylate cyclase leading to an increase in the intracellular con­
centration of cyclic guanosine 3', 5' monophosphate. SIN-1 
also hyperpolarizes the cell membrane by influencing the so­
dium-potassium pump,1 4 thus rendering the smooth muscle cell 
less responsive to adrenergically mediated contraction. The 
actions of the papaverine-phentolamine combination and of 
SIN-1 are not dependent on an intact endothelium, which 
should make both alternatives effective also in cases when the 
erectile dysfunction may be due to endothelial malfunction, 
such as in diabetes mellitus or hypercholesterolemia.15"17 Our 
series suggests SIN-1 to be comparable or even superior to the 
combination of papaverine and phentolamine. However, con­
trolled comparative studies are needed to strengthen these 
assumptions. Furthermore, the reasons for possible differences 
in efficacy remain to be established. 
In 4 of 63 patients who received SIN-1 neither 45 mg. 
papaverine plus 1.5 mg. phentolamine, 40 μg. prostaglandin E l 
nor 10 μg. prostaglandin E l plus 5 ßg. calcitonin gene-related 
peptide induced an erectile response allowing intercourse (even 
with additional stimulation). In 2 of these 4 patients intracav-
ernous injection of SIN-1 combined with stimulation induced 
a full erection, thus enabling the patients to have intercourse 
without the insertion of a penile prosthesis or application of a 
vacuum device. We have no explanation for the apparent better 
efficacy of SIN-1 in these patients. It is known that the number 
of prostaglandin E l receptors is reduced in several diseases, 
such as diabetes mellitus, 1 8 and that this may contribute to a 
lesser effect. In such cases SIN-1 may be an effective alterna-
tive. 
A 1 mg. dose of SIN-1 was injected into 6 patients with long 
lasting full erections to small doses of the papaverine-phentol-
amine combination. History revealed a spinal cord injury (com-
plete below T i l ) in 1 patient and a vertebral nucleus prolapse 
(L4/L5) in 1. In 4 patients abnormal single potential analysis 
of cavernous electrical activity findings was obtained, with the 
other examinations being normal. With a mean dose of 0.33 
ml. (5 mg. papaverine and 0.16 mg. phentolamine) 4 of 6 men 
had a mean duration of a full erection of 230 minutes (2 of 
them presented with episodes of prolonged erections). One 
patient was transferred to us because of multiple prolonged 
erections about 40 hours in duration with doses of 20 mg. 
papaverine. The diagnostic constellation in these 7 patients is 
highly suggestive of pure neurogenic impotence. Although these 
patients are usually overreactive to intracavernous pharmaco-
therapy, intracavernous injection of 1 mg. SIN-1 induced a full 
erection lasting 40 to 90 minutes (mean 57 minutes). This 
finding may be explained by the local pharmacokinetics of SIN-
1 and the rapid decomposition of nitric oxide within the cav-
ernous tissue, which should prevent the occurrence of prolonged 
erections. 
Most patients on autoinjection therapy with a papaverine-
phentolamine mixture report a slight burning sensation at the 
injection site during injection of the drug mixture. No patient 
who received SIN-1 intracavernously reported any pain or 
burning sensation during or after the injection. This observa-
tion may further indicate the fact that SIN-1 is well tolerated 
by the cavernous tissue. 
In animal studies19 as well as at followup of patients on 
autoinjection therapy,2 0 chronic intracavernous injection of pa-
paverine has been shown to result in significant cavernous 
fibrosis. Chronic intracavernous injection of prostaglandin E l 
seems to have less fibrotic potential on cavernous tissue, as 
shown in animal 1 9 and human studies.20 Since SIN-1 is deliv-
ered as lyophilized powder to be dissolved in physiological 
(0.9%) saline solution, i t should also have minor fibrotic effects 
on the cavernous tissue. Nevertheless, chronic animal studies 
are urgently needed to elucidate this important issue. Since 
therapy costs are of increasing importance in all countries, the 
cost of SIN-1 therapy is of interest (the prices indicated are 
those for Germany and France, respectively). The cost of 1 
ampule of SIN-1 (1 mg. delivered lyophilized with 1 ampule 
0.9% saline solution) equals approximately the cost of an am-
pule of papaverine (30 mg. in solution) and is approximately 
one-fifth of the cost of prostaglandin E l (20 fig. lyophilized, 
delivered without solution for dissolution). Thus, SIN-1 seems 
to be an affordable alternative in the treatment of erectile 
dysfunction. 
In conclusion, our preliminary results suggest that SIN-1 is 
an attractive option in the autoinjection therapy for erectile 
dysfunction. The absence of prolonged erections, the high ef-
fectiveness to induce a sufficient erectile response and the low 
cost indicate the potential of SIN-1 to become a standard drug 
for intracavernous injections. Before widespread use can be 
advocated, long-term animal studies must examine the local 
effect of this agent on the cavernous tissue. 
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